Status:
RECRUITING
A Phase 1 Study to Assess the Effect of ABBV-722 on Ethinyl Estradiol and Levonorgestrel Drug Levels in Healthy Adult Female Participants
Lead Sponsor:
AbbVie
Conditions:
Healthy Volunteer
Eligibility:
FEMALE
18-65 years
Phase:
PHASE1
Brief Summary
The objective of this study is to assess the effect of repeated doses of ABBV-722 on the single dose pharmacokinetics (PK) of ethinyl estradiol and levonorgestrel.
Eligibility Criteria
Inclusion Criteria:
- Laboratory values meet the criteria specified in the protocol.
- A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile, and a 12-lead electrocardiogram (ECG).
Exclusion Criteria:
- History of any clinically significant illness/infection/major febrile illness, hospitalization, or any surgical procedure within 30 days prior to the first dose of study treatment.
- Consumption of alcohol, grapefruit products, Seville oranges, starfruit products or quinine/tonic water within the 72-hour period prior to study treatment administration.
- Use of tobacco- or nicotine-containing products within 3 months (90 days) prior to the first dose of study treatment.
- Participant has prior exposure to ABBV-722 within 90 days prior to the first dose of study treatment.
Key Trial Info
Start Date :
March 25 2026
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2026
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT07502417
Start Date
March 25 2026
End Date
July 1 2026
Last Update
March 31 2026
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Acpru /Id# 281745
Grayslake, Illinois, United States, 60030